Anavex Life Sciences Corp (AVXL)

[falconer66a]

Real price catalyst will be NYT article.

Again, not sure what catalyst, if any is needed, is required for revaluation to occur.

Yes, has been so frustrating. Over the years, research articles, murine and human studies, professional accounts (Dr. Hagerman, et al.) have shown the profound safety and efficacies of blarcamesine in the treatment of human central nervous system (CNS) diseases. Now, becoming recognized (at least by a few) will be the profound prophylactic (disease prevention) applications.

When compared to the few other approved or yet in test CNS disease drugs, blarcamesine soars distantly above them. But the AVXL share price, instead of soaring like the pharmaceutical eagle that it is, remains a bottom-feeding fish, never getting out of the water.

Fact is, the massive general, retail stock investment community, the millions of moms and pops deciding to buy a few stock shares from time to time, continue to search the skies for strong, soaring equities. AVXL, right now, can’t be seen in those ascending equity vistas. It’s still submerged.

That, however, will dramatically change when the perceived “smart people” at, say, the New York Times, start to present articles telling about a “new drug has real promise against CNS diseases.” Those articles will appear when the results of the three on-going CNS clinical trials of blarcamesine are released. The results from the Rett study will be very positive; will prompt the first NYT article. It, of course, will strongly proclaim that the study showed that Rett could be usefully treated, but “other blarcamesine trials with other CNS disease are not yet complete.” A good start, to help turn minds toward Anavex.

Then, the next really big article will be how blarcamesine successfully treated Parkinson’s disease dementia. The Times writers’ cautions about consequently projecting blarcamesine on out to Alzheimer’s will not be so strong. Two CNS diseases with very positive blarcamesine outcomes.

Finally, in 2023, the big blarcamesine Alzheimer’s study results. Try as much as they’d prefer, the NYT writers will be forced to accurately tell how blarcamesine “will now transform CNS disease medicine.”

Then, a look back at the things we all discussed (and anguished over) on this stock investment board, will be curiosities. Twenty-first century medicine will be transforming in the manner that antibiotics and polio vaccines transformed twentieth-century medicine. (Well, even more so.)

None of that will be lost on any segment of the investment community, from small-time retail investors (like myself), on up.... Several authors will then be recounting the Anavex story, in books on the NYT Best Sellers List.

And, we were there at the start.